78967
document
Treatment of bladder cancer with intravesical instillation of adriamycin . Intravesical treatment with adriamycin has been extensively employed in the last decade . In the treatment of carcinoma in situ complete responses have been reported in about 60 % of cases . Its efficacy is probably lower in the therapy of multiple or diffuse low stage transitional cell carcinoma that is too extensive to be completely resected by conventional transurethral surgery . In such circumstances , including cancer in situ , adriamycin compares favorably with other local forms of treatment . The prophylactic use of intravesical instillation of Adriamycin has been studied more extensively . Preliminary results of controlled randomized trials implemented from the EORTC Urological Group show that adriamycin instillations significantly reduce recurrence rate after TUR . The treatment is well tolerated . Systemic absorption is virtually absent , and no severe drug-related side effects have ever been reported . Chemical cystitis is occasionally observed , especially if multiple instillations are started immediately after TUR , or in the presence of additional inflammatory conditions , such as previous irradiation or bacterial cystitis .
78968
Intervention_Pharmacological
adriamycin
78969
Intervention_Pharmacological
adriamycin
78970
Intervention_Pharmacological
adriamycin
78971
Intervention_Pharmacological
Adriamycin
78972
Intervention_Pharmacological
adriamycin
78973
Outcome_Other
efficacy
78974
Outcome_Physical
recurrence rate after TUR .
78975
Outcome_Other
tolerated .
78976
Outcome_Physical
Systemic absorption
78977
Outcome_Adverse-effects
no severe drug-related side effects
78978
Outcome_Adverse-effects
Chemical cystitis
78979
Participant_Condition
bladder cancer